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Controlled Human Hookworm Infection: Accelerating 
Human Hookworm Vaccine Development
David Diemert,1,2 Doreen Campbell,1 Jill Brelsford,1 Caitlyn Leasure,1 Guangzhao Li,1 Jin Peng,1 Maria Zumer,2 Naji Younes,3 Maria Elena Bottazzi,4 
Rojelio Mejia,4 David I. Pritchard,5 John M. Hawdon,1,* and Jeffrey M. Bethony1,*
1Department of Microbiology, Immunology and Tropical Medicine, 2Department of Medicine, and 3Milken Institute School of Public Health, The George Washington University, Washington DC; 
4Department of Pediatrics, Section of Pediatric Tropical Medicine, Texas Children’s Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, 
Houston, Texas; 5Department of Pharmacy, University of Nottingham, Nottingham, United Kingdom
Background. Controlled human hookworm infection (CHHI) is a central component of a proposed hookworm vaccina-
tion-challenge model (HVCM) to test the efficacy of candidate vaccines. Critical to CHHI is the manufacture of Necator americanus 
infective larvae (NaL3) according to current Good Manufacturing Practice (cGMP) and the determination of an inoculum of NaL3 
that is safe and reliably induces patent infection.
Methods. cGMP-grade NaL3 were produced for a phase 1 trial in 20 healthy, hookworm-naïve adults in the United States, who 
received either 25 or 50 NaL3. Participants were monitored for 12–18 weeks postinfection for safety, tolerability, and patency of 
N. americanus infection.
Results. Both NaL3 doses were well tolerated. Early manifestations of infection included pruritus, pain, and papulovesicular 
rash at the application site. Gastrointestinal symptoms and eosinophilia appeared after week 4 postinfection. The 50 NaL3 inoculum 
induced patent N. americanus infection in 90% of this dose group.
Conclusions. The inoculum of 50 NaL3 was well tolerated and consistently induced patent N. americanus infection suitable for 
future HVCM trials.
Clinical Trials Registration. NCT01940757.
Keywords. challenge model; controlled human hookworm infection; current good manufacturing practice; hookworm vaccine; 
Necator americanus.
 
More than 400 million individuals are infected with hookworms, 
hematophagic nematodes that parasitize the host gastrointestinal 
tract [1]. Chronic hookworm infection can induce iron deficiency 
anemia, with children and women of childbearing age being most 
at risk [2]. Current control efforts rely on mass drug adminis-
tration (MDA) with a benzimidazole (BZ) that cures established 
infections but does not prevent re-infection [3]. Furthermore, 
development of resistance to BZs, as seen in livestock [4, 5], is a 
significant concern. Given the limitations of MDA, a preventative 
human hookworm vaccine (HHV) is being developed. The cur-
rent HHV candidate antigens, Na-GST-1 and Na-APR-1, have 
been evaluated in clinical trials in the United States, Brazil, and 
Gabon and have been found to be safe and immunogenic [6, 7].
The next stage of clinical development for the HHV is to 
assess vaccine efficacy, which conventionally requires costly 
field trials in Necator-endemic areas, with large sample sizes 
(~1200 volunteers) and lengthy duration (1–2  years) [8]. To 
mitigate the expense and risk of such trials, we propose a hook-
worm vaccination-challenge model (HVCM) to provide early 
proof of concept of vaccine efficacy that would entail immuniz-
ing hookworm-naïve adults from nonendemic areas with candi-
date vaccines and then challenging them with infective Necator 
americanus larvae (NaL3). Efficacy would be determined by the 
absence of patent infection (no detectable eggs in feces) or a 
reduction in infection intensity (expressed by eggs per gram 
[EPG] of feces) compared with unvaccinated controls [7, 9, 10].
Although hookworm-naïve volunteers have been infected 
with N.  americanus in prior studies [11–20], we report the 
first trial in which NaL3 produced according to current Good 
Manufacturing Practice (cGMP) were administered to healthy 
volunteers to determine the tolerability of different doses and to 
establish an effective inoculum for future HVCM trials.
METHODS
cGMP Manufacture of NaL3
Necator americanus larvae were manufactured by the 
Immune Modulation Research Group (IMRG) at the 
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University of Nottingham, United Kingdom, under an 
Investigational Medicinal Product Dossier from the UK 
Medicines and Healthcare products Regulatory Agency 
(UK MIA [IMP] 3057). Briefly, feces were collected from a 
chronically infected volunteer who was screened for com-
municable agents considered relevant for topically applied 
investigational medicinal products, per 21CFR§1271.3(r)
(1) (Supplementary Methods). Fecal material was mixed 
with amphotericin B and gentamicin for 6 hours, to which 
activated charcoal (Fisher Scientific, Loughborough, UK) 
was added, and incubated for 10 days at 28ºC according to 
a modified Harada Mori method to recover NaL3 [21, 22].
Recovered NaL3 were isolated and washed repeatedly in ster-
ile water. NaL3 batches were tested for viability (motility), iden-
tity (lectin-binding assay), and microbial contamination (USP 
<61> and <62>, and then released by IMRG (Supplementary 
Methods) and transported to George Washington University 
(GWU) at 19ºC–25ºC in a temperature-monitored container. 
Microbial contamination was retested according to USP <61> 
and <62>) for total aerobic microbial and combined yeast and 
mold counts, as well as the absence of Staphylococcus aureus 
and Pseudomonas aeruginosa, after arrival at GWU and prior 
to application in the clinical trial under an US Food and Drug 
Administration (FDA) Investigational New Drug (IND) appli-
cation (#015752).
Study Design
The phase 1 trial (NCT01940757) was an open-label dose 
escalation study of 20 healthy, hookworm-naïve adults aged 
18–45 years at the George Washington University (Washington, 
DC). In Cohort 1, 10 volunteers received an inoculum of 25 
NaL3; in Cohort 2, they received 50 NaL3. NaL3 were pipetted 
onto a sterile gauze pad, which was applied to the volar aspect 
of the forearm and covered with an adhesive bandage for 1 hour. 
After removal, the gauze was placed into sterile water to count 
residual NaL3.
Cohorts were enrolled in a staggered fashion, with at least 8 
weeks of safety data assessed by a Safety Monitoring Committee 
prior to dose escalation. Participants were evaluated 3, 7, 14, 
and 28  days postinfection (p.i.) and then weekly until treat-
ment with 3 daily doses of 400 mg albendazole on day 84 for the 
first 14 participants, and on day 126 for the last 6. At each visit, 
application sites were examined for erythema, swelling, and 
tenderness. Solicited symptoms included fever, abdominal pain 
or bloating, nausea, vomiting, diarrhea, cough, and sore throat. 
Participants completed daily symptom diaries for the duration 
of their infections.
Adverse events were graded as mild (easily tolerated), mod-
erate (interfered with activities of daily living), or severe (pre-
vented activities of daily living) and assigned causality relative 
to NaL3. Complete blood counts were performed prior to 
NaL3 application and at regular time points starting at week 5 
(Supplementary Methods). The study was approved by the 
GWU Institutional Review Board (IRB), and written informed 
consent was obtained from all volunteers. Inclusion and exclu-
sion criteria are listed in the Supplementary Methods.
Detection of Patency
Beginning 5 weeks p.i., fecal samples were examined weekly 
by both saline flotation and quantitative polymerase chain 
reaction (qPCR) methods to detect N.  americanus eggs [10]. 
Samples were further analyzed by the McMaster (MM) tech-
nique and qPCR to assess intensity of infection, expressed as 
EPG of feces [9].
Statistical Analysis
Time to patent infection was displayed using Kaplan-Meier 
estimates, with log-rank tests used to compare the distribu-
tion of time to patency between dose groups and censoring of 
early withdrawals or those failing to develop patent infection. 
Proportions with patent infection were compared between dose 
groups by the Fisher exact test. Locally weighted regression was 
used to display trends in eosinophil counts and fecal EPGs by 
study day. Mann-Whitney U tests were used to evaluate differ-
ences in EPG and eosinophil counts between dose groups and 
study day. Sign tests were used to determine if median eosino-
phil counts were above the upper limit of the normal range. 
A  Cox proportional hazards model was used to evaluate the 
effects of covariates (eg, NaL3 dose or eosinophil count) on 
time to patency. A generalized linear mixed-effects model was 
constructed using the PROC GLIMMIX procedure to deter-
mine the effects of eosinophil count and NaL3 dose on EPG 
levels quantified by MM or qPCR. To compare the accuracy 
of infection intensity, as measured by MM and qPCR, signed 
rank tests were used to evaluate differences between EPG deter-
mined by the 2 methods. Receiver operating characteristic 
(ROC) curves were used to compare the accuracy of MM and 
qPCR in discriminating between patency and no patency, with 
the saline flotation method used as the gold standard. Analyses 
were conducted using SAS, version 9.3 (Cary, NC), and figures 
were constructed using R software (version 3.3.2).
Power Calculations for HVCM
Data from the current study were used to calculate the sample 
sizes required for the HVCM. Primary sample size analysis was 
based on comparing the proportion of individuals with patent 
infection in the 3 intervention groups (ie, 3 different vaccine 
formulations) with the proportion with patent infection in a 
control (placebo) group using a 1-sided Fisher exact test, for 
a total of 3 comparisons. The Holm-Bonferroni procedure was 
used to control the familywise error rate at .05.
RESULTS
Of 31 adults screened, 6 declined or were lost to follow-up 
before enrollment, 5 were ineligible, and 20 (5 males and 5 
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females in each of the 2 cohorts) met eligibility criteria and 
were enrolled (Supplementary Figure 1). Reasons for exclusion 
were concomitant medical diagnoses such as irritable bowel 
syndrome, Hashimoto’s thyroiditis, and iron deficiency anemia. 
The median age of enrolled participants (range) was 25 (19–45) 
years. Two participants in the 50 NaL3 cohort agreed to partic-
ipate in an IRB-approved substudy and were not treated with 
albendazole but have remained infected to serve as donors of 
fecal samples, from which N. americanus eggs will be produced 
for future HVCM studies. Mean percentages of residual larvae 
were 5.60% and 5.40% for the 25 and 50 NaL3 cohorts, respec-
tively (P = .56, Wilcoxon rank-sum test).
Safety of CHHI
Application of NaL3 to healthy, hookworm-naïve adults was 
well tolerated. No participants were withdrawn or required early 
treatment due to adverse events or discomfort (1 participant in 
Cohort 1 withdrew early and was treated with albendazole on 
day 63 due to moving unexpectedly from the area). Common 
reactions consisted of early skin reactions at NaL3 application 
sites and later gastrointestinal symptoms. NaL3 application 
site reactions were mostly mild to moderate rash and pruritus 
(Table 1). Rash occurred in 9/10 and 10/10 participants in the 25 
and 50 NaL3 cohorts, respectively, and ranged from maculopap-
ular to vesicular (Figure 1). Rashes were mild in severity, except 
for 1 moderate case in the 25 NaL3 cohort; topical corticoster-
oids were used in 6/20 participants for symptom relief. Onset of 
rash was typically noted immediately upon removal of the gauze 
pad following NaL3 application and lasted a median (range) 
of 26 (4–69) days. Residual skin hyperpigmentation occurred 
in 3 participants in the 50 NaL3 cohort and lasted a median of 
107 days after resolution of the rash; in 2 cases, the hyperpig-
mentation was still present, albeit fading, at the final visit.
Gastrointestinal complaints were common (Table  1) and 
occurred primarily after week 4  p.i. (Figure  2). The incidence 
and timing of these symptoms were not significantly different 
between the 2 dose cohorts (Supplementary Table 1). Increased 
flatulence (7/10 in the 25 NaL3 cohort and 3/10 in the 50 NaL3 
cohort), abdominal bloating (7/10 in both cohorts), and abdom-
inal pain (8/10 in the 25 NaL3 cohort and 5/10 in the 50 NaL3 
cohort) were the most common gastrointestinal complaints, all of 
which were mild or moderate in severity. Four episodes of vom-
iting occurred in 3 participants in the 25 NaL3 cohort, although 
Table 1. Incidence and Severity of Application Site, Respiratory and Gastrointestinal Solicited Adverse Reactions Following Application of 25 or 50 NaL3 
by CHHI
25 NaL3 (n = 10) 50 NaL3 (n = 10)
Mild Moderate Severe Mild Moderate Severe
No. No. No. No. No. No.
Application site reactions
Rash 8 1 – 10 – –
Pruritus 10 – – 8 2 –
Pain 1 – – 4 – –
Tenderness 4 – – 8 – –
Swelling 2 – 1 4 1 –
Bruising 3 – – 1 – –
Respiratory reactions
Sore throat 2 2 – 7 – –
Cough 2 2 – 7 – –
Gastrointestinal reactions
Abdominal bloating 4 3 – 4 2 –
Abdominal pain 5 3 – 3 2 –
Nausea 3 2 – 3 2 –
Vomiting 1 2 – – – –
Diarrhea 3 2 – 5 – –
Flatulence 6 – – 1 1 –
Data are number of participants experiencing an event. Participants with more than 1 occurrence of the same adverse reaction are recorded only once, at the maximum severity experienced.
Abbreviation: CHHI, controlled human hookworm infection.
A B
Figure 1. Representative images of rash induced by application of NaL3 to the 
forearm. A, Day 7 postapplication of 25 NaL3. B, Day 35 postapplication of 50 NaL3.
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none were considered related to CHHI. Other solicited adverse 
events possibly related to infection with N. americanus included 
respiratory symptoms due to larvae transiting through the lungs 
and upper airways. Cough was reported by 6 and 4 participants 
in the 25 and 50 NaL3 cohorts, respectively, while 4 and 7 partic-
ipants complained of transient sore throat. The median onset of 
respiratory symptoms (range) was 2 (8–43) days p.i. 
Patent Infection and Intensity of Infection
Fifty NaL3 resulted in significantly more (9/10 vs 3/10) partici-
pants developing patent N. americanus infection, as determined 
by saline flotation, than 25 NaL3 (P = .02), whereas 40% (n = 4) 
of the 25 NaL3 group had patent infection, as determined by 
qPCR, compared with 90% (n  =  9) with 50 NaL3 (Figure  3). 
The difference in the proportion with patent infection when 
measured by qPCR between the 2 groups was just above the 
level of significance (P  =  .06). A  significant difference was 
found between the 25 and 50 NaL3 groups in the distribution of 
time to patency based on Kaplan-Meier curves (P = .04) when 
assessed by qPCR, although not by saline flotation (P = .11).
Two participants in the 25 NaL3 cohort had eggs in feces quan-
tifiable by MM, ranging from 16.67 to 33.33 EPG (Figure 4A). 
Four of the 25 NaL3 cohort with patent infections, as determined 
by qPCR, had quantifiable eggs in feces, also by qPCR (range, 
1.5–123.6 EPG). Nine in the 50 NaL3 cohort had quantifiable 
egg counts by both MM and qPCR, ranging from 16.33 to 166.66 
EPG by MM and from 1.2 to 373.2 EPG by qPCR (Figure 4). 
When compared by study day, there were no statistically signifi-
cant differences in distribution of EPG or “visit-to-visit” changes 
in EPG between dose groups (Supplementary Table 2).
There were no statistically significant differences in the distri-
bution of time to patency or intensity of infection by either MM 
or qPCR. MM was slightly more accurate than qPCR by ROC 
curve analysis. Using saline flotation as the gold standard, the 
value of the area under the curve (AUC) for detecting fecal eggs 
using the MM (AUCMM, 0.97) was greater than that for qPCR 
(AUCqPCR, 0.88), although the difference was not significant 
(P = .16) (Figure 5).
Eosinophil Counts
Those who received 50 NaL3 had a more rapid and greater 
increase in eosinophil count that declined faster than in those 
who received 25 NaL3 (Figure  6). Starting at 49 and 42  p.i., 
median eosinophil levels in volunteers in the 25 and 50 NaL3 
dose groups increased significantly (both P  <  .02) above the 
upper limit of the normal range and remained high until treat-
ment. Eosinophilia peaked 56 and 42 days p.i. for the 25 and 50 
NaL3 groups, respectively. When compared on each study day, 
there were no statistically significant differences in distribu-
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Figure 2. Prevalence of gastrointestinal symptoms by study week. Bar graph represents sum of participants in each dose cohort who experienced abdominal pain, abdom-
inal bloating, nausea, vomiting, or diarrhea that was assessed as being related to controlled human hookworm infection. A, 25 NaL3 cohort. B, 50 NaL3 cohort.
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Figure 3. Time to patency for controlled Necator americanus infection as shown by Kaplan-Meier curves for volunteers exposed to either 25 N. americanus third-stage 
larvae (NaL3), as shown by the red line, or 50 NaL3, as shown by the blue line. Solid lines represent the proportion of individuals in the dose group with patent N. americanus 
infection, as detected by saline flotation, while dotted lines represent the proportion with patent infection, as determined by quantitative polymerase chain reaction. Crosses 
indicate censored data. Abbreviation: qPCR, quantitative polymerase chain reaction.








































Figure 4. Eggs per gram (EPG) of feces, as determined by the McMaster (A) and quantitative polymerase chain reaction (B) methods for controlled human hookworm infec-
tion with an inoculum of 25 Necator americanus third-stage larvae (NaL3), as shown by the red line, or 50 NaL3, as shown by the blue line. Each dot represents the median 
EPG of the inoculum group by study day, and the solid lines show the trend in EPG for each inoculum group using locally weighted regression. The gray shading shows the 
upper and lower boundaries of the 95% confidence interval around the trend line.
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Table 3). However, “visit-to-visit” changes in eosinophil count 
declined significantly faster (P  =  .03) in the 50 NaL3 cohort 
compared with the 25 NaL3 cohort from days 70 to 77.
Interaction Between Eosinophil Counts and NaL3 Dose on Time to 
Patency 
In a Cox regression model, neither NaL3 dose nor eosinophil count 
significantly predicted the probability of patent N.  americanus 
infection (P > .05). In addition, 50 NaL3 resulted in a 2.72 times 
(P = .15) or 2.55 times (P = .12) greater probability of patency than 
25 NaL3, as determined by saline flotation or qPCR, respectively.
Eosinophil Count and Infection Intensity
Longitudinal fecal egg counts were analyzed using a general-
ized linear mixed-effects model with random intercept and an 
unstructured covariance matrix. The response variable EPG 
was assumed to have a Poisson distribution, and residual pseu-
do-likelihood was used as the estimation procedure. The dose 
of NaL3 and the eosinophil count induced by each dose pre-
dicted intensity of infection (EPG) when quantified either by 
MM or qPCR (P < .001). Parameters associated with EPG are 
reported in Supplementary Table 4.
Power Calculations for HVCM
Assuming a rate of 90% patent hookworm infection, as observed 
in the 50 NaL3 dose cohort in the current study, and a greater 
than 80% rate of protection in at least 1 of 3 vaccination groups 
(eg, different doses or adjuvant formulations) compared with 
controls who did not receive the hookworm vaccine, a sample 
size of 48 (12 per group) would be sufficient to demonstrate the 
efficacy of a prophylactic hookworm vaccine such as Na-GST-1 
or Na-APR-1, at an alpha of 0.05/3 and a power of 87.7%.
DISCUSSION
This manuscript describes the first administration of NaL3 
obtained from a human donor and manufactured under cGMP 
conditions to infect hookworm-naïve volunteers in a clinical 
trial in the United States. Moreover, this is the first CHHI trial 
to be conducted under an IND with the FDA. As such, the 
results enable us to use CHHI to test the efficacy of experimen-
tal hookworm vaccines in an HVCM under the existing US reg-
ulatory framework.
Both the 25 and 50 NaL3 inocula were safe and well toler-
ated, with application site and gastrointestinal reactions being 
the most common adverse events in both groups. Of note, skin 
reactions (mild to moderate pruritus, pain, erythema, and rash) 
occurred in most participants, lasted several weeks in a minor-
ity, and in some participants resulted in residual hyperpig-
mentation. Interestingly, the dermatologic findings were more 
significant and prolonged than reported in previous CHHI 
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Figure 5. Receiver operator characteristic curves comparing the accuracy (area under the curve) of quantitative polymerase chain reaction with the conventional McMaster 
method to indicate patency (eggs in stool) from controlled human hookworm infection with 50 Necator americanus third-stage larvae (NaL3) using the saline flotation tech-
nique as the gold standard. Abbreviations: AUC, area under the curve; MM, McMaster; PCR, polymerase chain reaction.
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moderate in severity and coincided with onset of patency. All 
participants stated that they would participate in the study 
again if given the opportunity.
Fifty NaL3 induced a significantly higher proportion of pat-
ent N.  americanus infections than 25 NaL3 and also resulted 
in quantifiable fecal egg counts by conventional MM or qPCR. 
One possible explanation for the lower rate of patency in the 25 
NaL3 group is that fewer NaL3 applied to the forearm traversed 
the dermis and lungs and succeeded in migrating to the intes-
tine, or, if they did reach the intestine, they were too few in 
number to have resulted in effective mating. Based on these 
data, we estimate for an HVCM trial that 50 NaL3 would be suf-
ficient to demonstrate the efficacy of an experimental vaccine 
using only 48 individuals divided into 3 groups (eg, different 
doses or formulations) compared with an unvaccinated control 
group, with 12 volunteers per group (Supplementary Figure 2).
The current CHHI study enabled an unprecedented observa-
tion of the host response to N. americanus infection. As skin-pene-
trating nematodes, NaL3 have been thought to traverse the dermis 
within 48–72 hours p.i., with 98% traversing the lungs within the 
first 120 hours p.i., after which they undergo tracheo-esopha-
geal migration and enter the lumen of the gastrointestinal tract 
for the fourth molt [24]. As we have shown, marked eosinophilia 
was observed in both dose groups, although 50 NaL3 resulted in 
a significantly earlier onset, higher peak, and more rapid decline 
than 25 NaL3. Eosinophilia during experimental hookworm 
infection has long been thought to coincide with larvae traversing 
lung parenchyma [13, 25]. However, as described in animal mod-
els [26], NaL3 may have already reached the gastrointestinal tract 
by 14 days p.i., in which case development of eosinophilia would 
be concomitant with initiation of blood feeding and recruitment 
of inflammatory cells to feeding sites [25].
The current study allowed comparisons between conven-
tional coprological methods such as the saline flotation and 
McMaster techniques with novel molecular methods (qPCR) for 
the detection of N. americanus eggs. Both conventional meth-
ods detected the same time to patency, while qPCR detected 
more patent infections in the 25 NaL3 group than conventional 
techniques. No difference was observed in measurements of 
infection intensity by MM or qPCR. However, the MM method 
was slightly more accurate than qPCR, as determined by ROC 
analysis (Figure 5). The main advantage of qPCR is that frozen 
fecal samples can be used, whereas conventional coprological 
methods require fresh specimens.
The incorporation of CHHI into hookworm vaccine clinical 
development would dramatically improve the efficiency of vac-
cine efficacy testing. Currently, efficacy studies for a preventa-
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Figure 6. Peripheral eosinophil counts of volunteers infected with 25 Necator americanus third-stage larvae (NaL3) in red or 50 NaL3 in blue. Dots represent median 
eosinophil counts by study day, and the lines show the trend of eosinophil counts for each cohort using locally weighted regression. The upper and lower boundaries of the 
95% confidence interval around the trend line are depicted by the gray shading.
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endemic areas prior to vaccination and determining efficacy by 
comparing incidence of reinfection or mean intensity of reinfec-
tion. Such a trial would require a sample size of approximately 
1200 volunteers and last for several years [8]. However, an 
HVCM trial would last only 3 months following completion of 
vaccinations and require far fewer volunteers (eg, 12 adults per 
group, with 1 group serving as unvaccinated infectivity controls), 
such that multiple vaccine candidates or adjuvant formulations 
could be assessed simultaneously to facilitate rapid downselec-
tion of the most promising product for phase 3 efficacy testing.
Our findings support the use of CHHI as a tool to assess 
hookworm vaccine efficacy and provide the framework for 
ensuring reproducible and accurate results that can be used to 
justify regulatory applications for efficacy testing. Moreover, for 
the concept of using controlled hookworm infection as a poten-
tial therapeutic for autoimmune and allergic diseases [12, 15, 
23, 27], production of high-quality NaL3 in compliance with 
cGMP and administration to study participants according to 
current Good Clinical Practice will be required.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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